ArriVent BioPharma, Inc.

AVBP

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001868279

SEC filings (opens in a new tab)

No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Q1 2024 vs. Q4 2023

How the institutions holding ArriVent BioPharma, Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024 All holders in Q4 2023

13F holders of AVBP: Q4 2023 compared with Q1 2024
Measure	Q4 2023	Q1 2024	Change
Holders	0	53	+53
Shares	0	21.9M	+21.9M
Value	$0	$388.9M	+$388.9M

New holders (53)

Institutions that held ArriVent BioPharma, Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to AVBP in Q1 2024
Institution	Shares	Value	% of portfolio
HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse)	3,929,117	$70.2M	1.52%
OrbiMed Advisors LLC	3,027,328	$54.1M	1.06%
FMR LLC	1,950,034	$34.8M	0.00%
Octagon Capital Advisors LP	1,943,836	$34.7M	4.22%
Sofinnova Investments, Inc.	1,696,752	$30.3M	1.79%
Suvretta Capital Management, LLC	1,563,709	$27.9M	1.18%
General Catalyst Group Management, LLC	1,494,786	$26.7M	2.05%
Novo Holdings A/S	1,077,140	$19.2M	1.33%
BlackRock Inc.	654,804	$11.7M	0.00%
Vanguard Group Inc	648,735	$11.6M	0.00%
SC China Holding Ltd	663,308	$10.5M	0.97%
Altitude Crest Partners Inc.	555,555	$9.92M	4.25%
Cormorant Asset Management, LP	515,000	$9.20M	0.41%
Perceptive Advisors LLC	415,000	$7.41M	0.13%
Citadel Advisors LLC	286,512	$5.12M	0.00%
Geode Capital Management, LLC	225,049	$4.02M	0.00%
Millennium Management LLC	211,689	$3.78M	0.00%
Farallon Capital Management, L.L.C.	151,768	$2.71M	0.02%
State Street Corp	122,264	$2.18M	0.00%
Woodline Partners LP	100,000	$1.79M	0.02%
AlphaCentric Advisors LLC	83,000	$1.48M	0.89%
Northern Trust Corp	78,409	$1.40M	0.00%
Charles Schwab Investment Management Inc	77,760	$1.39M	0.00%
Ghisallo Capital Management LLC	50,000	$893.0K	0.10%
Jane Street Group, LLC	36,959	$660.1K	0.00%
MYDA Advisors LLC	30,000	$535.8K	0.19%
Point72 Asset Management, L.P.	28,900	$516.2K	0.00%
UBS Oconnor LLC	26,181	$467.6K	0.01%
Blackstone Group Inc.	25,000	$446.5K	0.00%
Walleye Capital LLC	25,000	$446.5K	0.00%
Bank of New York Mellon Corp	22,707	$405.5K	0.00%
Point72 (DIFC) Ltd	21,890	$390.9K	0.03%
Morgan Stanley	21,141	$377.6K	0.00%
Barclays PLC	14,208	$253.8K	0.00%
Nuveen Asset Management, LLC	12,932	$231.0K	0.00%
JPMorgan Chase & Co	12,556	$224.3K	0.00%
UBS Group AG	9,895	$176.7K	0.00%
Rhumbline Advisers	9,765	$174.4K	0.00%
MetLife Investment Management	5,514	$98.5K	0.00%
American International Group, Inc.	4,845	$86.5K	0.00%
BNP Paribas Arbitrage, SA	4,659	$83.2K	0.00%
Cubist Systematic Strategies, LLC	4,360	$77.9K	0.00%
Wells Fargo & Company	3,231	$57.7K	0.00%
Bank of America Corp	2,259	$40.3K	0.00%
Citigroup Inc	1,741	$31.1K	0.00%
STRS Ohio	1,700	$30.0K	0.00%
California State Teachers Retirement System	989	$17.7K	0.00%
Ameritas Investment Partners, Inc.	981	$17.5K	0.00%
Legal & General Group Plc	896	$16.1K	0.00%
Tower Research Capital LLC (TRC)	604	$10.8K	0.00%
Metropolitan Life Insurance Co	567	$10.1K	0.00%
Amalgamated Bank	540	$10.0K	0.00%
Royal Bank of Canada	369	$7.00K	0.00%

Sold out (0)

Institutions that held ArriVent BioPharma, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.

None.